Research programme: hepatitis C virus therapeutics - Arrow Therapeutics

Drug Profile

Research programme: hepatitis C virus therapeutics - Arrow Therapeutics

Alternative Names: HCV polymerase inhibitors - Arrow Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arrow Therapeutics
  • Class Pyrimidines
  • Mechanism of Action Polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Hepatitis-C in United Kingdom
  • 02 Oct 2008 Lead optimisation of HCV polymerase inhibitors is ongoing
  • 17 Jan 2007 A-689 from this programme enters full preclinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top